- Home
- SLRN
SLRN
ACELYRIN INC.
as 11-21-2024 10:38am EST
Acelyrin Inc is a late-stage clinical biopharmaceutical company. It is focused on providing patients life-changing new treatment options by identifying, acquiring, and accelerating development and commercialization of of transformative medicines.
| Founded: | 2020 | Country: | United States |
| Employees: | N/A | City: | AGOURA HILLS |
| Market Cap: | 485.6M | IPO Year: | 2023 |
| Target Price: | $11.50 | AVG Volume (30 days): | 463.0K |
| Analyst Decision: | Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.68 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.36 - $8.89 | Next Earning Date: | 11-13-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest ACELYRIN INC. News
SLRN Breaking Stock News: Dive into SLRN Ticker-Specific Updates for Smart Investing
GuruFocus.com
7 days ago
Acelyrin Inc (SLRN) Q3 2024 Earnings Call Highlights: Strategic Pipeline Refocus and Financial ...
GlobeNewswire
8 days ago
ACELYRIN, INC. Reports Third Quarter 2024 Financial Results and Recent Highlights
GlobeNewswire
15 days ago
ACELYRIN, INC. to Report Third Quarter 2024 Financial Results and Corporate Update on November 13, 2024
GlobeNewswire
a month ago
ACELYRIN, INC. Forms Scientific and Patient Advisory Board Featuring Leading Voices in Thyroid Eye Disease
GlobeNewswire
2 months ago
ACELYRIN, INC. Announces Positive Results from Global Phase 3 Clinical Trial of Izokibep in Hidradenitis Suppurativa to be Highlighted in Late-Breaking Oral Presentation at EADV 2024
GuruFocus.com
2 months ago
Significant Acquisition by T. Rowe Price Investment Management in Acelyrin Inc
GlobeNewswire
2 months ago
ACELYRIN, INC. Announces Positive Proof-of-Concept Data From Phase 1/2 Clinical Trial of Lonigutamab as a Subcutaneous Treatment for Thyroid Eye Disease to be Presented at 42nd Annual Meeting of European Society of Ophthalmic Plastic and Reconstructive Surgery
GlobeNewswire
3 months ago
ACELYRIN, INC. to Participate in Upcoming Investor Conferences
Compare SLRN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SLRN ACELYRIN INC. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.